Unaudited Preliminary Results for the Year Ended December 31, 2025

Tue, 19 May 2026 02:14:00 -0400

LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").

FY25 Highlights

Research & Development (R&D) Highlights

Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
Gen Two (AVA6103):
- LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
  
  FY25 Highlights
  
  Research & Development (R&D) Highlights
  - Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
  - Gen Two (AVA6103):
    - LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
      
      FY25 Highlights
      
      Research & Development (R&D) Highlights
      - Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
      - Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):
        
        LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
        
        FY25 Highlights
        
        Research & Development (R&D) Highlights
        
        Increased momentum and strengthened position as a pure-play oncology biopharmaceutical company by focusing on the Company’s unique proprietary pre|CISION® peptide drug conjugate platform, with significant progress in R&D programs
        
        Gen Two (AVA6103):

StreetInsider.com News Articles

Unaudited Preliminary Results for the Year Ended December 31, 2025